SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT…
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors…
MANSFIELD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, announced…
– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral…
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today…
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the…
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected…